Table 2.

Study characteristics of included studies for clinical outcomes associated with de-escalation

Study	Design	Country	Study N	Ticagrelor group (n)	Timing of de-escalation—with reasonsa	Follow-up duration
Biscaglia et al. [26]	Prospective Cohort	Italy	586	Ticagrelor followed by clopidogrel (n = 101)	Varied—need for OAT, bleeding, intolerance, unwillingness, dyspnea	12 months
Hamid [32]	Retrospective Cohort	United Kingdom	98	Ticagrelor + aspirin followed by clopidogrel + aspirin (n = 50)	3 months—NR	12 months
Wang et al. [35]	Prospective Cohort	China	417	Ticagrelor followed by clopidogrel (subgroup) (n = 44)	In-hospital or at discharge—NR	6 months
Motovska et al. [37]	RCT	Czech Republic	1230	Ticagrelor followed by clopidogrel (pooled with or without bolus) (n = 265)	Varied—economic	12 months
Pourdjabbar et al. [38]	RCT	Canada	60	Ticagrelor followed by clopidogrel (n = 60/57b)	Randomization—triple therapy, bleeding risk, cost, needing CABG, compliance concerns	30 days
Xu et al. [39]	RCT	China	114	Ticagrelor + aspirin followed by clopidogrel + aspirin (n = 57)	1 week—study protocol	Periprocedural

CABG coronary artery bypass graft, NR not reported, OAT oral anticoagulant, RCT randomized controlled trial

^aReasons reported in at least 10% of those who de-escalated are listed

^bNumber of patients enrolled/number of patients analyzed